The bill aims to lower prescription drug costs by removing obstacles that hinder access to biosimilar medications. It focuses on promoting the use of more affordable biosimilars by addressing barriers such as patent thickets and anti-competitive practices. By increasing competition in the market, the bill seeks to reduce drug prices and improve patient access to cost-effective treatments.
2023-01-16: First reading, referred to Health Care & Wellness.
2024-01-08: By resolution, reintroduced and retained in present status.
Contribute Your Insights: Add a Unique Perspective to Political Bills. Your Contribution will be Featured Below the Primary Bill, Ordered by Date Added.
No Reviews found ..